JPWO2021021882A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021021882A5 JPWO2021021882A5 JP2022506056A JP2022506056A JPWO2021021882A5 JP WO2021021882 A5 JPWO2021021882 A5 JP WO2021021882A5 JP 2022506056 A JP2022506056 A JP 2022506056A JP 2022506056 A JP2022506056 A JP 2022506056A JP WO2021021882 A5 JPWO2021021882 A5 JP WO2021021882A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- conjugate
- antibody
- tumor
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 63
- 210000004881 tumor cell Anatomy 0.000 claims description 27
- 239000000835 fiber Substances 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 16
- 239000001007 phthalocyanine dye Substances 0.000 claims description 15
- 230000002601 intratumoral effect Effects 0.000 claims description 14
- 229960002621 pembrolizumab Drugs 0.000 claims description 12
- 230000036039 immunity Effects 0.000 claims description 11
- 230000001394 metastastic effect Effects 0.000 claims description 11
- 230000009885 systemic effect Effects 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 10
- 229940121497 sintilimab Drugs 0.000 claims description 8
- 230000002195 synergetic effect Effects 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 229960004669 basiliximab Drugs 0.000 claims description 6
- 229940121420 cemiplimab Drugs 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 6
- 229960003301 nivolumab Drugs 0.000 claims description 6
- 229950007213 spartalizumab Drugs 0.000 claims description 6
- 210000003289 regulatory T cell Anatomy 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000001516 cell proliferation assay Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 229940125568 MGD013 Drugs 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 230000006052 T cell proliferation Effects 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 229960000106 biosimilars Drugs 0.000 claims description 3
- 229950007712 camrelizumab Drugs 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 229940067219 cetrelimab Drugs 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960002806 daclizumab Drugs 0.000 claims description 3
- 229940121432 dostarlimab Drugs 0.000 claims description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000005252 lipomatous cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000000578 peripheral nerve Anatomy 0.000 claims description 3
- 229950010773 pidilizumab Drugs 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 201000002060 skeletal muscle cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000000267 smooth muscle cancer Diseases 0.000 claims description 3
- 208000028647 spindle cell neoplasm Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000005737 synergistic response Effects 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 229950007123 tislelizumab Drugs 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 2
- 230000003836 peripheral circulation Effects 0.000 claims description 2
- 210000004988 splenocyte Anatomy 0.000 claims description 2
- 230000004565 tumor cell growth Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880514P | 2019-07-30 | 2019-07-30 | |
| US62/880,514 | 2019-07-30 | ||
| US201962896453P | 2019-09-05 | 2019-09-05 | |
| US62/896,453 | 2019-09-05 | ||
| US201962931405P | 2019-11-06 | 2019-11-06 | |
| US62/931,405 | 2019-11-06 | ||
| PCT/US2020/043999 WO2021021882A1 (en) | 2019-07-30 | 2020-07-29 | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antybody-phthalocyanine dye conjugate and anti-pd1 antibody |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022543765A JP2022543765A (ja) | 2022-10-14 |
| JPWO2021021882A5 true JPWO2021021882A5 (https=) | 2023-08-04 |
| JP2022543765A5 JP2022543765A5 (https=) | 2023-08-04 |
| JP7627259B2 JP7627259B2 (ja) | 2025-02-05 |
Family
ID=72047165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506056A Active JP7627259B2 (ja) | 2019-07-30 | 2020-07-29 | 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220313822A1 (https=) |
| EP (1) | EP4004048A1 (https=) |
| JP (1) | JP7627259B2 (https=) |
| CN (1) | CN114423453A (https=) |
| TW (1) | TW202118518A (https=) |
| WO (1) | WO2021021882A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119564879A (zh) | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| AU2016308286B2 (en) | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| TW202133886A (zh) * | 2019-12-06 | 2021-09-16 | 美商樂天醫藥生技股份有限公司 | 用於增強免疫及腫瘤治療之方法 |
| WO2022182483A1 (en) * | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| CA3260932A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD25-SPECIFIC ANTIBODIES AND THEIR USES |
| EP4662238A1 (en) * | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103781495A (zh) * | 2011-07-11 | 2014-05-07 | 美国政府(由卫生和人类服务部的部长所代表) | 光敏抗体-荧光团缀合物 |
| SG11201610052TA (en) * | 2014-08-08 | 2017-02-27 | Us Health | Photo-controlled removal of targets in vitro and in vivo |
| CN108137701A (zh) * | 2015-08-07 | 2018-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit) |
| CN119564879A (zh) * | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| RU2740793C2 (ru) | 2016-10-25 | 2021-01-21 | Ракутен Медикал, Инк. | Светорассеивающие устройства для использования в фотоиммунотерапии |
| US10416366B2 (en) | 2016-10-25 | 2019-09-17 | Rakuten Medical, Inc. | Light diffusing devices for use in photoimmunotherapy |
| US11685782B2 (en) * | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| CA3096305A1 (en) * | 2018-04-10 | 2019-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation |
-
2020
- 2020-07-29 JP JP2022506056A patent/JP7627259B2/ja active Active
- 2020-07-29 TW TW109125563A patent/TW202118518A/zh unknown
- 2020-07-29 US US17/630,854 patent/US20220313822A1/en active Pending
- 2020-07-29 WO PCT/US2020/043999 patent/WO2021021882A1/en not_active Ceased
- 2020-07-29 CN CN202080065407.6A patent/CN114423453A/zh active Pending
- 2020-07-29 EP EP20754590.6A patent/EP4004048A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4729503B2 (ja) | 抗癌剤の奏効率増強剤 | |
| Tang et al. | Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma | |
| Malik et al. | Futuristic approach to cancer treatment | |
| JP5623016B2 (ja) | 癌治療法およびそれに用いる医薬組成物 | |
| JP2014132009A5 (https=) | ||
| JP2008501630A6 (ja) | 抗癌剤の効果増強剤 | |
| JP2012500180A5 (https=) | ||
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| US20220313822A1 (en) | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody | |
| UA130036C2 (uk) | Спосіб лікування стійкого до інгібітору cdk4/6 раку | |
| Serre et al. | Brachytherapy: perspectives for combined treatments with immunotherapy | |
| JPWO2021021882A5 (https=) | ||
| Xia et al. | Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma | |
| CN111773388B (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
| JPWO2021113734A5 (https=) | ||
| JP2019513826A (ja) | 放射線療法の改善 | |
| Peng et al. | Tumor therapeutic modes | |
| Białczyk et al. | Abscopal effect in solid tumors. Potential mechanisms, application of radioimmunotherapy, and a review of exemplary clinical cases | |
| JP7098518B2 (ja) | 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用 | |
| JPWO2021108682A5 (https=) | ||
| US12472227B2 (en) | Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy | |
| CN109674788A (zh) | 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途 | |
| Swamy | Stereotactic Body Radiotherapy Immunological Planning–Road to Abscopal Effect by Design | |
| EP4213845A1 (en) | New use of inhibitors of the notch signalling pathway |